NuPathe to Present at the Leerink Swann 2013 Global Healthcare Conference

NuPathe to Present at the Leerink Swann 2013 Global Healthcare Conference 
CONSHOHOCKEN, PA -- (Marketwire) -- 02/06/13 --  NuPathe Inc.
(NASDAQ: PATH), a specialty pharmaceutical company focused on the
development and commercialization of branded therapeutics for
diseases of the central nervous system, today announced that Armando
Anido, chief executive officer, will present a company overview at
the Leerink Swann 2013 Global Healthcare Conference on Wednesday,
February 13, 2013, at 2:30 p.m. EST. The conference is being held at
the Waldorf Astoria in New York, NY. 
A live audio webcast of the presentation will be available via the
"Investor Relations" page of the NuPathe website,
Please log on through NuPathe's website approximately 10 minutes
prior to the scheduled start time. A replay of the webcast will also
be archived on NuPathe's website for 90 days following the
About NuPathe
 NuPathe Inc. is a specialty pharmaceutical company
focused on innovative neuroscience solutions for diseases of the
central nervous system including neurological and psychiatric
disorders. NuPathe's lead product candidate, Zecuity(TM) (sumatriptan
iontophoretic transdermal system) has been approved by the FDA for
the acute treatment of migraine with or without aura in adults.
Zecuity is expected to be available by prescription in the fourth
quarter of 2013. In addition to Zecuity, NuPathe has two proprietary
product candidates based on its LAD(TM), or Long-Acting Delivery,
biodegradable implant technology that allows delivery of therapeutic
levels of medication over a period of months with a single dose.
NP201, for the continuous symptomatic treatment of Parkinson's
disease, utilizes a leading FDA-approved dopamine agonist,
ropinirole, and is being developed to provide up to two months of
continuous delivery. NP202, for the long-term treatment of
schizophrenia and bipolar disorder, is being developed to address the
long-standing problem of patient noncompliance by providing three
months of continuous delivery of risperidone, an atypical
antipsychotic. NuPathe is actively seeking partnerships to maximize
the commercial potential for Zecuity and its other product candidates
in the U.S. and territories throughout the world. 
For more information about NuPathe, please visit our website and our
blog at You can also follow us on StockTwits
(, Twitter (, SlideShare
( and LinkedIn ( 
Cautionary Note Regarding Forward-Looking Statements 
 This press
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. All statements
that are not historical facts are hereby identified as
forward-looking statements for this purpose and include, among
others, statements relating to: the potential benefits of, and
commercial opportunity for, Zecuity and NuPathe's other product
candidates; partnering plans for Zecuity and NuPathe's other product
candidates; the timing of the expected launch and availability of
Zecuity; and other statements relating to NuPathe's plans,
objectives, expectations and beliefs regarding its future operations,
performance, financial condition and other future events.
Forward-looking statements are based upon management's current
expectations and beliefs and are subject to a number of risks,
uncertainties, assumptions and other factors that could cause actual
results and events to differ materially from those indicated herein
including, among others: NuPathe's ability to obtain sufficient
capital to launch Zecuity; NuPathe's ability to obtain commercial and
development partners for Zecuity and its other product candidates;
NuPathe's reliance on third parties to manufacture Zecuity; NuPathe's
ability to establish and effectively manage its supply chain;
NuPathe's ability to establish effective marketing and sales
capabilities; market acceptance among physicians and patients and the
availability of adequate reimbursement from third party payors for
Zecuity; and the risks, uncertainties and other factors discussed in
NuPathe's Annual Report on Form 10-K for the year ended December 31,
2010 and Quarterly Report on Form on Form 10-Q for the quarter ended
September 30, 2012 under the caption "Risk Factors" and elsewhere in
such reports, which are available on NuPathe's website at in the "Investor Relations -- SEC Filings" section.
While NuPathe may update certain forward-looking statements from time
to time, it specifically disclaims any obligation to do so, whether
as a result of new information, future developments or otherwise. You
are cautioned not to place undue reliance on any forward-looking
Contact Information: 
Investor Contacts 
John Woolford
Westwicke Partners, LLC
(443) 213-0506 
Keith A. Goldan
Vice President & Chief Financial Officer
NuPathe Inc.
(484) 567-0130  
Press spacebar to pause and continue. Press esc to stop.